Cofactor Genomics Unveils New Data Showing Novel OncoPrism Diagnostic is Nearly Twice as Accurate as PD-L1 in Identifying Immunotherapy Responders

2022-09-08

合作免疫疗法

San Francisco, California--(News - September 8, 2022) - Cofactor Genomics, a Predictive Immune Modeling company, today presented initial results from the PREDAPT (Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies) multicenter clinical trial at this week's Advances in Genome Biology and Technology Precision Health Meeting. Data show that Cofactor's OncoPrism test using Predictive Immune Modeling was nearly twice as accurate as PD-L1 assays in determining patients that will benefit from immunotherapies such as Keytruda (pembrolizumab). To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Data presented at AGBT Precision Health show that Cofactor's technology is more predictive than PD-L1 assays OncoPrism-HNSCC outperforms PD-L1 in patient cohorts from decentralized, multisite clinical trial Cofactor's multidimensional biomarker approach will be used in 11 cancers through the PREDAPT trial Click image above to view full announcement. About PREDAPT Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies (PREDAPT) is a national clinical trial sponsored by Cofactor Genomics working and in collaboration with the leaders in decentralized clinical trials, CureBase. The trial's goal is to evaluate the predictive power of Cofactor's Predictive Immune Modeling approach and the biomarkers generated to predict which patients will ultimately benefit from immune checkpoint inhibitors across 11 cancers. About Cofactor Genomics Cofactor Genomics is bridging the precision medicine gap by building diagnostic tools to match the right patient to the right treatment at the right time. Predicting patient response to therapy currently relies on isolated, single-analyte biomarkers that have failed to deliver accurate therapy response predictions, resulting in unnecessary healthcare costs, and most harmfully, negative outcomes for patients. Cofactor's products use Predictive Immune Modeling, which leverages RNA data and machine learning to combine biological signals, creating multidimensional biomarkers to deliver on the promise of precision medicine. Cofactor Genomics offers its full-service molecular, informatic, and database tools to make drug discovery, clinical trials and therapy selection more successful. Contacts: Tim Baker 919.969.3492 tim.baker@mrnacommunications.com Source: Cofactor Genomics To view the source version of this press release, please visit

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构